We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+29.4%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.45B
AUM Growth
+$253M
Cap. Flow
-$255M
Cap. Flow %
-7.4%
Top 10 Hldgs %
43.88%
Holding
127
New
16
Increased
25
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$62.7M
2
BLU
BELLUS Health Inc.
BLU
+$50.1M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$48.2M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$42.4M
5
EW icon
Edwards Lifesciences
EW
+$31.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$38.2M
2
LLY icon
Eli Lilly
LLY
+$32.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.2M
5
CHRS icon
Coherus Oncology
CHRS
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 98.21%
2 Miscellaneous 1.6%
3 Financials 0.19%
4 Consumer Staples 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
26
DELISTED
RAPT Therapeutics
RAPT
$41.2M 1.2%
214,142
-25,082
-10% -$4.74M
VBIV
27
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$37.2M 1.08%
1,744,500
– –
TMCI icon
28
Treace Medical Concepts
TMCI
$298M
$35.4M 1.03%
1,601,979
+660,787
+70% +$12.8M
NUVL
29
DELISTED
Nuvalent
NUVL
$32.2M 0.93%
1,655,007
– –
ESTA icon
30
Establishment Labs
ESTA
$2.13B
$31.6M 0.92%
578,253
+172,494
+43% +$10.3M
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$12.5B
$28.5M 0.83%
336,481
+156,481
+87% +$13.9M
SRPT icon
32
Sarepta Therapeutics
SRPT
$2.19B
$28M 0.81%
+253,000
New +$25.5M
EW icon
33
Edwards Lifesciences
EW
$49.4B
$27.3M 0.79%
+330,000
New +$31.8M
ZYME icon
34
Zymeworks
ZYME
$1.86B
$27.1M 0.79%
4,400,099
+267,565
+6% +$1.61M
ADMA icon
35
ADMA Biologics
ADMA
$1.93B
$26.6M 0.77%
10,933,387
-587,715
-5% -$1.41M
VRDN icon
36
Viridian Therapeutics
VRDN
$2.47B
$25M 0.73%
1,220,575
+248,743
+26% +$4.47M
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$25M 0.73%
366,400
+45,100
+14% +$2.67M
IMTX icon
38
Immatics
IMTX
$1.31B
$25M 0.73%
2,500,000
– –
CMAX
39
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$24.1M 0.7%
113,165
+13,165
+13% +$2.66M
TARS icon
40
Tarsus Pharmaceuticals
TARS
$3.66B
$22.2M 0.64%
1,296,416
– –
RVNC
41
DELISTED
Revance Therapeutics, Inc.
RVNC
$21.8M 0.63%
808,671
+236,157
+41% +$4.79M
MDGL icon
42
Madrigal Pharmaceuticals
MDGL
$12.1B
$21.5M 0.62%
331,023
-36,478
-10% -$2.53M
NAUT icon
43
Nautilus Biotechnolgy
NAUT
$113M
$19.3M 0.56%
9,111,151
– –
CTKB icon
44
Cytek Biosciences
CTKB
$636M
$19M 0.55%
+1,289,534
New +$16.7M
OM icon
45
Outset Medical
OM
$59M
$18.6M 0.54%
77,909
+11,327
+17% +$3.03M
ISEE
46
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18.6M 0.54%
1,034,169
-1,053,787
-50% -$13.8M
HRMY icon
47
Harmony Biosciences
HRMY
$2.46B
$18.2M 0.53%
411,804
– –
RCUS icon
48
Arcus Biosciences
RCUS
$3.1B
$17.4M 0.51%
+666,477
New +$17.6M
BBIO icon
49
BridgeBio Pharma
BBIO
$13.4B
$16.9M 0.49%
1,697,033
– –
AORT icon
50
Artivion
AORT
$1.24B
$16.7M 0.48%
1,204,229
+274,524
+30% +$5.53M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Perceptive Advisors held 127 positions worth $3.45B, up 7.9% from $3.19B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $255M in Q3 2022, closing 11 positions and reducing 24 holdings. Its most notable exit was Eli Lilly, an estimated $32.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Edwards Lifesciences worth $27.3M.

  • Perceptive Advisors's largest Q3 2022 buy was Edwards Lifesciences: 330,000 shares worth $27.3M.
  • Perceptive Advisors added most to Relmada Therapeutics in Q3 2022, an estimated $62.7M increase.
  • Perceptive Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $38.2M.
  • Perceptive Advisors fully exited Eli Lilly in Q3 2022, selling an estimated $32.4M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q3 2022.
  • Perceptive Advisors opened 16 new positions and closed 11 in Q3 2022.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.